Prescription drug

Lowering apolipoprotein B (apoB)

Prescription drug.

How to take it

There is no established standard dose for this case; it is advisable to consult a professional.

Effect by goal · level of evidence

Cardiovascular risk

reduces Very high meta-analysis (AAA)

Meta-analysis of 29 trials: lowering apoB with therapies that increase the LDL receptor (statins, ezetimibe, PCSK9 inhibitors) reduces cardiovascular events; those that lower apoB through other pathways are less consistent. It reinforces apoB as a key target of risk.

View the study (meta-analysis) →

In depth

Drug · Highest evidence: Very high · 1 finding

Findings

Cardiovascular risk — reduces (Very high, meta-analysis). Meta-analysis of 29 trials: lowering apoB with therapies that increase the LDL receptor (statins, ezetimibe, PCSK9 inhibitors) reduces cardiovascular events; therapies that lower apoB through other pathways are less consistent. Reinforces apoB as a key target for risk. 31475865

Information, not medical advice. Prescription drugs require a doctor.

Information, not medical advice. Scientific evidence reflects the quality of the studies.